



International Parkinson and
Movement Disorder Society
Pan American Section



1st Pan American Parkinson's Disease
and Movement Disorders Congress

Program-at-a-Glance

FEBRUARY 24-26, 2017 MIAMI, FLORIDA, USA

www.pascongress2017.org





Congress Schedule-At-A-Glance

	Friday, February 24	Saturday, February 25	Sunday, February 26
8:00			
8:30			
9:00		Plenary Session 8:00 - 10:00	Plenary Session 8:00 - 9:30
9:30			Break 19:30 - 10:00
10:00	Plenary Session 9:30 - 11:00	Break 10:00 - 10:30	
10:30			
11:00	Break 11:00 - 11:30	Plenary Session 10:30 - 12:00	Plenary Session 10:00 - 12:00
11:30			
12:00		Break 12:00 - 12:15	Break 12:00 - 12:15
12:30	Plenary Session 11:30 - 13:30	Corporate Therapeutic Symposia 12:15 - 13:15	Corporate Therapeutic Symposia 12:15 - 13:15
13:00			
13:30	Break 13:30 - 14:30	Break & Poster Session/ Guided Poster Tours 13:00 - 14:30	Break & Poster Session/ Guided Poster Tours 13:00 - 14:30
14:00			
14:30			
15:00			
15:30	Plenary Session 14:30 - 16:30	Parallel Sessions 14:30 - 16:30	Parallel Sessions 14:30 - 16:30
16:00			
16:30	Break 16:30 - 17:00	Break 16:30 - 17:00	
17:00			
17:30	Parallel Sessions 17:00 - 19:00	Skills Workshops 17:00 - 18:30	
18:00			
18:30		Break 18:30 - 19:00	
19:00			
19:30	Opening Ceremony 19:00 - 21:00	Video Tournament 19:00 - 21:00	
20:00			
20:30			
21:00			
21:30			
22:00			



Scan to learn more
on our website

Dear Colleagues,

The International Parkinson and Movement Disorder Society (MDS) is pleased to introduce the **1st Pan American Parkinson's Disease and Movement Disorders Congress**. The meeting will be held on February 24-26, 2017 in Miami, Florida, USA.

As a result of the rapid growth of the MDS Pan American Section (MDS-PAS), there is the need for a forum to discuss relevant issues in our field that are specific to the Pan American Section. The 1st PAS Congress will incorporate practical workshops and ensure geographic and gender diversity in speaker selection and incorporate lecture topics that are cutting edge for both clinicians and basic scientists. This will also be a tremendous opportunity for MDS-PAS members to network with colleagues from different parts of Pan America.

Please visit www.pascongress2017.org to learn more about this inaugural event.

Warmest regards,



A handwritten signature in cursive script that reads "Cynthia Comella".

Cynthia Comella
Chair, PAS Congress Scientific
Program Committee



A handwritten signature in cursive script that reads "Francisco Cardoso".

Francisco Cardoso
Chair, MDS Pan American Section





Friday, February 24, 2017

1101 Themed Plenary Session

Parkinson's Disease Across the Americas 9:30 – 11:00

- Chairs: Oscar Gershanik
Buenos Aires, Argentina
Stanley Fahn
New York, NY, USA
- 9:30 How Levodopa Therapy for Parkinson's Disease Came to be Developed in the Americas
Stanley Fahn
New York, NY, USA
- 10:00 Parkinson's Disease Genetics Across the Americas
Jeffery Vance
Miami, FL, USA
- 10:30 Therapeutics: Accessibility, Cultural Differences and Habits Across the Americas
Oscar Gershanik
Buenos Aires, Argentina

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the emergence of levodopa as a treatment for Parkinson's disease: the American experience
2. Discuss the polymorphisms and risk alleles of the different populations in the Americas
3. Recognize how cultural differences, ingrained habits and access to different treatment options determine therapeutic decisions across the Americas

1102 Plenary Session

From Bench to Bedside - Clinico-Pathological Markers of Parkinson's Disease 11:30 – 13:30

- Chairs: Sarah Camargos
São Paulo, Brazil
Jennifer Goldman
Chicago, IL, USA
- 11:30 Evidence for a Systemic Synucleinopathy
C. Warren Olanow
Rye, NY, USA
- 12:10 The Potential Role of Tissue and Fluid Biomarkers
Kathleen Shannon
Madison, WI, USA

1102 Plenary Session, cont.

- 12:50 The Spread of Synuclein in Parkinson's Disease
Jeffrey Kordower
Chicago, IL, USA

Recommended Audience: Basic scientists, Clinical academicians, Health Professionals (non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Review the latest scientific findings regarding the presence of synuclein in the central and peripheral nervous system in Parkinson's disease
2. Discuss recent data on the potential role of a tissue and fluid biomarkers
3. Discuss theories and evidence regarding the spread of synuclein in the pathogenesis of Parkinson's disease

1103 Plenary Session

Update on Parkinson's Disease Therapeutics 14:30 – 16:30

- Chairs: Federico Micheli
Buenos Aires, Argentina
David Standaert
Birmingham, AL, USA
- 14:30 Levodopa: Old Drug, New Approaches
Robert Hauser
Tampa, FL, USA
- 15:10 Next Generation Deep Brain Stimulation
Jill Ostrem
Greenbrae, CA, USA
- 15:50 Non-Motor Therapies: Present and Future
Federico Micheli
Buenos Aires, Argentina

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize how new delivery strategies are expanding the application of levodopa
2. Describe how newer techniques and technologies may impact use of DBS
3. Recognize current and emerging therapies for non-motor symptoms of Parkinson's disease

1204 Parallel Session

Dopaminergic and Cholinergic Imaging in Parkinson's Disease 17:00 – 19:00

- Chairs: A. Jon Stoessl
Vancouver, BC, Canada
Antonio Strafella
Toronto, ON, Canada
- 17:00 Presynaptic Dopaminergic Imaging and its Role in Parkinson's Disease
A. Jon Stoessl
Vancouver, BC, Canada
- 17:40 Imaging in Behavioral and Cognitive Complications in Parkinson's Disease
Antonio Strafella
Toronto, ON, Canada
- 18:20 Insights From Cholinergic Imaging in Parkinson's Disease
Nicolaas Bohnen
Saline, MI, USA

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the clinical and research utility of different presynaptic dopaminergic PET tracers in Parkinson's disease
2. Recognize how dopaminergic imaging contributes to the understanding of cognitive and behavioral complications of Parkinson's disease
3. Describe the insights provided by cholinergic imaging on the pathophysiology of non-dopaminergic features of Parkinson's disease

Friday, February 24, 2017

1205	Parallel Session	1206	Themed Parallel Session 
	Surgical Procedures in Movement Disorders 17:00 – 19:00		Drug- Or Toxin-Induced Movement Disorders in America 17:00 – 19:00
Chairs:	Corneliu Luca <i>Miami, FL, USA</i> Jill Ostrem <i>Greenbrae, CA, USA</i>	Chairs:	Pedro Chana-Cuevas <i>Santiago, Chile</i> Caroline Tanner <i>San Francisco, CA, USA</i>
17:00	Lesions Versus Deep Brain Stimulation Corneliu Luca <i>Miami, FL, USA</i>	17:00	Metal Exposure and Movement Disorders Marcelo Miranda <i>Santiago, Chile</i>
17:40	Latin America Experiences with Subthalamotomy Jose Obeso <i>Madrid, Spain</i>	17:40	Toxin-Induced Movement Disorders Caroline Tanner <i>San Francisco, CA, USA</i>
18:20	Focused Ultrasound William Jeffrey Elias <i>Charlottesville, VA, USA</i>	18:20	Drug-Induced Movement Disorders Pedro Chana-Cuevas <i>Santiago, Chile</i>
Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees		Recommended Audience: Basic Scientists, Clinical academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
1. Identify the factors that contribute to patient candidacy for various surgical treatments of Parkinson's disease		1. Recognize the role of metal exposure (manganese, iron) in movement disorders	
2. Recognize the regional variability of surgical procedures performed for Parkinson's disease and the long-term management of such patients		2. Recognize the pathogenic role of toxin (MPTP, Rotenone and Paraquat) in movement disorders	
3. Recognize the utility of focused ultrasound in the treatment of movement disorders		3. Describe the movement disorders associated with the use of drugs, from psychotropics to non psychotropics and identify clues leading to the suspicion of drug-induced movement disorders	



Saturday, February 25, 2017

2101 Themed Plenary Session

Hyperkinetic Movement Disorders in Ethnic Populations in the Americas 8:00 – 10:00

- Chairs: Francisco Cardoso
Belo Horizonte, Brazil
- Rachel Saunders-Pullman
New York, NY, USA
- 8:00 Hyperkinetic Movement Disorders in the Amish-Mennonite Population
Rachel Saunders-Pullman
New York, NY, USA
- 8:40 Genetic Dystonia in Brazil
Sarah Camargos
São Paulo, Brazil
- 9:20 Huntington's Disease-Like 2 and Other Huntington's Disease-Like Diseases in the Americas
Ruth Walker
Bronx, NY, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the hyperkinetic movement disorders found in the Amish-Mennonite population
2. Recognize the heterogeneity of genetic dystonias in Brazil
3. Discuss the epidemiology, genetics, and clinical features of HD like diseases in the Americas

2102 Plenary Session

Huntington's Disease Update 10:30 – 12:00

- Chairs: Emilia Gatto
Buenos Aires, Argentina
- Blair Leavitt
Vancouver, BC, Canada
- 10:30 History of Huntington's Disease in the Americas
Roberto Weiser
Caracas, Venezuela
- 11:00 Phenotype-Genotype
Emilia Gatto
Buenos Aires, Argentina
- 11:30 Experimental Therapies in Huntington's Disease
Blair Leavitt
Vancouver, BC, Canada

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Identify the historical significance of the region in Huntington's disease development
2. Identify different phenotypes of Huntington's disease
3. Identify new therapeutic tools for Huntington's disease and cutting edge new therapies

2203 Parallel Session

Genetics of Parkinson's Disease 14:30 – 16:30

- Chairs: Karen Marder
Bronx, NY, USA
- Andrew Singleton
Bethesda, MD, USA
- 16:30 Genetics of Sporadic Parkinson's Disease
Andrew Singleton
Bethesda, MD, USA
- 15:10 Spectrum of LRRK2-and GBA-Associated Parkinson's Disease
Karen Marder
Bronx, NY, USA
- 15:50 Genetics of Cognitive Impairment in Parkinson's Disease
Ignacio Fernandez Mata
Seattle, WA, USA

Recommended Audience: Basic Scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

2203 Parallel Session , cont.

At the conclusion of this session, participants should be better able to:

1. Recognize the genetic contributions to the cause of Parkinson's disease
2. Describe the spectrum of different clinical characteristics seen in LRRK2 and GBA-associated Parkinson's disease
3. Discuss the contribution of genetic factors to the development of cognitive impairment in Parkinson's disease

2204 Parallel Session

Spinocerebellar Ataxias 14:30 – 16:30

- Chairs: Stefan Pulst
Los Angeles, CA, USA
- Mayela Rodriguez Violante
Mexico City, Mexico
- 14:30 Molecular Pathogenesis
Stefan Pulst
Los Angeles, CA, USA
- 15:10 Clinical Features and Work-Up
Anelyssa D'Abreu
Campinas, Brazil
- 15:50 Current Treatments and Future Directions
Theresa Zesiewicz
Oldsmar, FL, USA

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the role of polyglutamine expansion and other molecular issues on the pathophysiology of spinocerebellar ataxias
2. Recognize the main clinical features of the most prevalent spinocerebellar ataxias and improve the diagnostic approach
3. Provide management to subjects with spinocerebellar ataxia, including genetic counseling, rehabilitation, as well as current and future pharmacologic interventions

Saturday, February 25, 2017

2205 Parallel Session Parkinson's Disease Across the PAS: Cross-Cultural Influences on its Neuropsychiatric Issues 14:30 – 16:30 Chairs: Oscar Bernal-Pacheco <i>Chía, Colombia</i> Bonnie Levin <i>Miami, FL, USA</i> 14:30 Neuropsychiatric Features of Parkinson's Disease: Similarities and Differences Across the Americas Oscar Bernal-Pacheco <i>Chía, Colombia</i> 15:10 Cultural Influences on Perceptions and Treatments of Neuropsychiatric Features in Parkinson's Disease Jennifer Goldman <i>Chicago, IL, USA</i> 15:50 Neuropsychological Evaluations in Parkinson's Disease in the Context of Culture and Language Bonnie Levin <i>Miami, FL, USA</i> Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees At the conclusion of this session, participants should be better able to: 1. Describe the epidemiology and clinical features of neuropsychiatric problems affecting cognition, behavior, and mood in Parkinson's disease across the Pan Americas 2. Discuss how cultural differences influence our perceptions, recognition, and management of neuropsychiatric features in Parkinson's disease 3. Discuss the effects of cultural and language on neuropsychological testing, normative data, particularly in the evaluation of neuropsychiatric features of Parkinson's disease	2306 Skills Workshop Challenges to Publish Movement Disorders Research for Non-English Speakers 17:00 – 18:30 Christopher Goetz <i>Chicago, IL, USA</i> Marcelo Merello <i>Buenos Aires, Argentina</i> Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees At the conclusion of this session, participants should be better able to: 1. Recognize that publication of research starts before writing a paper 2. Identify different ways of publishing their research 3. Discuss the most common style mistakes made by non-English speakers when writing a paper 2307 Skills Workshop MDS-UPDRS and UDysRS 17:00 – 18:30 Mayela Rodriguez Violante <i>Mexico City, Mexico</i> Glenn Stebbins <i>Chicago, IL, USA</i> Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees At the conclusion of this session, participants should be better able to: 1. Describe the conceptual constructs of the MDS-UPDRS and UDysRS 2. Engage patients and caregivers in their role in the MDS-UPDRS and UDysRS 3. Complete sample ratings on items in the MDS-UPDRS and UDysRS	2308 Skills Workshop Chemodenervation in Movement Disorders 17:00 – 18:30 Chairs: Robert Chen <i>Toronto, ON, Canada</i> Joseph Jankovic <i>Bellaire, TX, USA</i> 17:00 Clinical and Pharmacological Aspects of Botulinum Toxins Joseph Jankovic <i>Bellaire, TX, USA</i> 17:30 Applications in Dystonia Cynthia Comella <i>Chicago, IL, USA</i> 18:00 Applications in Parkinsonism Robert Chen <i>Toronto, ON, Canada</i> Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees At the conclusion of this session, participants should be better able to: 1. Discuss the mechanisms of action and clinical pharmacological effects of the different formulations of Botulinum toxins 2. Describe the use of Botulinum toxin for the focal dystonias 3. Describe the use of Botulinum toxin in the treatment of the motor and non-motor manifestations of Parkinson's disease
--	--	--



Sunday, February 26, 2017

3101	Plenary Session	3102	Plenary Session	3203	Themed Parallel Session 
	Hot Topics in Movement Disorders 8:00 – 9:30		Controversies 10:00 – 12:00		Inflammation, Infections and Immunity in Movement Disorders 14:30 – 16:30
Chairs:	Jorge Juncos <i>Atlanta, GA, USA</i> Irene Litvan <i>La Jolla, CA, USA</i>	Chairs:	Cynthia Comella <i>Chicago, IL, USA</i> Marcelo Merello <i>Buenos Aires, Argentina</i>	Chairs:	Mayela Rodriguez Violante <i>Mexico City, Mexico</i> Helio Teive <i>Curitiba, Brazil</i>
8:00	Deep Brain Stimulation for Tourette's Syndrome Michael Okun <i>Gainesville, FL, USA</i>	10:00	Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (YES) Matthew Stern <i>Philadelphia, PA, USA</i>	14:30	Inflammation and Movement Disorders David Standaert <i>Birmingham, AL, USA</i>
8:30	Emerging Treatments for Tauopathies Irene Litvan <i>La Jolla, CA, USA</i>	10:20	Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (NO) Charles Adler <i>Scottsdale, AZ, USA</i>	15:10	Viral and Parasitic Infections Carlos Cosentino <i>Lima, Peru</i>
9:00	Stem Cell Tourism Carlos Singer <i>Fort Lauderdale, FL, USA</i>	10:40	Is There a Role for Immunotherapy for Synucleinopathies? (YES) Elvira Valera <i>La Jolla, CA, USA</i>	15:50	Post Infectious and Autoimmune Movement Disorders Francisco Cardoso <i>Belo Horizonte, Brazil</i>
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees		Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees		Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
1. Discuss current options for surgical intervention in Tourette's syndrome		1. Understand the difficulties of an early diagnosis in Parkinson's disease		1. Recognize the role of inflammation in the pathophysiology of movement disorders	
2. Recognize recent advances in the treatment of Tauopathies		2. Assess the promises and pitfalls of immunotherapy in Parkinson's disease		2. Identify the pathogenesis features of viral infection and parasitic causing movement disorders	
3. Discuss the risks of uncontrolled advertising of unsubstantiated stem cell treatments for neurodegenerative diseases		3. Discuss the value of clinical phenomenology vs. whole exome sequencing		3. Recognize the pathogenesis or post infectious and autoimmune movement disorders	

Sunday, February 26, 2017

3204	Parallel Session	3205	Parallel Session
	Focus on the Patient/Family: Completing the Circle of Care in the Americas 14:30 – 16:30		Rare Movement Disorders: What We Can Learn? 14:30 – 16:30
Chairs	Pedro Chana-Cuevas <i>Santiago, Chile</i> Ruth Hagestuen <i>Minnetonka, MN, USA</i>	Chairs:	Emilia Gatto <i>Buenos Aires, Argentina</i> Anthony Lang <i>Toronto, ON, Canada</i>
14:30	Focus on the Patient/Family: Completing the Circle of Care Ruth Hagestuen <i>Minnetonka, MN, USA</i>	14:30	Approach to Rare Movement Disorders Anthony Lang <i>Toronto, ON, Canada</i>
15:10	Home Management, Family and People with Parkinson's Disease Daniela Albuquerque <i>Santiago, Chile</i>	15:10	Neurodegeneration with Brain Iron Accumulation Susan Hayflick <i>Portland, OR, USA</i>
15:50	Palliative Care and Parkinson's Disease Julie Carter <i>Portland, OR, USA</i>	15:50	Gaucher Disease and Niemann Pick Type C Emilia Gatto <i>Buenos Aires, Argentina</i>
Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees		Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
1. Identify the impact of Parkinson's disease on the care partners in the early, middle and advanced stages of Parkinson's disease as well as options for support along the journey		1. Recognize rare movement disorders and explain how these conditions contribute to the understanding of more common disorders	
2. Distinguish different alternatives in Parkinson's disease care within the home, consider cultural and family perspective		2. Explain clinical and pathologic features of degenerative disorders with brain iron accumulation	
3. Identify key palliative care with respect to Parkinson's disease and how a palliative care approach can be used throughout the disease trajectory		3. Discuss the clinical features, diagnosis and treatment of Gaucher disease and Niemann Pick Type C	



Continuing Medical Education Information

Target Audience

The target participants of the 1st Pan American Congress are clinicians, researchers, medical residents, medical students and other non-physician health professionals who have an interest in the current research and issues in the field of movement disorders that are specific to the Pan American region.

Purpose

The purpose of the PAS Congress is consistent with the objectives of the MDS-PAS which include the following:

- Facilitate communication between clinicians and researchers in the region
- Disseminate updated knowledge about movement disorders
- Improve quality of life and independence of movement disorders patients and caregivers
- Promote research in Movement Disorders within the region
- Expose clinicians, researcher and healthcare professionals in the region to Movement Disorder initiatives and in so doing, encourage their membership in the MDS-PAS

Learning Objectives:

Through state-of-the-art lectures, hot topic reviews, controversy debates and Skills Workshops, participants will be better able to:

1. Describe the pathophysiology and neurobiology of Parkinson's disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders
3. Discuss the pharmacological and non-pharmacological treatment options available for Parkinson's disease and other movement disorders

Intended Physician Competency Change (Attributes clinicians will gain/enhance due to participation in this activity):

- Provide patient-centered care
- Employ evidence-based practice
- Increase medical knowledge
- Practice-based learning and improvement
- Commitment to lifelong learning
- Cognitive expertise

Accreditation Statement:

The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The International Parkinson and Movement Disorder Society designates this educational activity for a maximum of 20 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Important Dates

September 1, 2016
Abstract Submission Deadline

January 24, 2017
Final Pre-Registration Deadline

February 24-26, 2017
1st Pan American Parkinson's Disease
and Movement Disorders Congress



Scan to learn more on our website!

